Transglutaminase 2 (TGase 2) is a multifunctional protein which is involved in various physiological and pathophysiological processes. The latter also include its participation in the development and progression of malignant neoplasms, which are often accompanied by increased protein synthesis. In addition to the elucidation of the molecular functions of TGase 2 in tumor cells, knowledge of its concentration that is available for targeting by theranostic agents is a valuable information. Herein, we describe the application of a recently developed fluorescence anisotropy (FA)-based assay for the quantitative expression profiling of TGase 2 by means of transamidase-active enzyme in cell lysates. This assay is based on the incorporation of rhodamine B-isonipecotyl-cadaverine (R-I-Cad) into N,N-dimethylated casein (DMC), which results in an increase in the FA signal over time. It was shown that this reaction is not only catalyzed by TGase 2 but also by TGases 1, 3, and 6 and factor XIIIa using recombinant proteins. Therefore, control measurements in the presence of a selective irreversible TGase 2 inhibitor were mandatory to ascertain the specific contribution of TGase 2 to the overall FA rate. To validate the assay regarding the quality of quantification, spike/recovery and linearity of dilution experiments were performed. A total of 25 cancer and 5 noncancer cell lines were characterized with this assay method in terms of their activatable TGase 2 concentration (fmol/µg protein lysate) and the results were compared to protein synthesis data obtained by Western blotting. Moreover, complementary protein quantification methods using a biotinylated irreversible TGase 2 inhibitor as an activity-based probe and a commercially available ELISA were applied to selected cell lines to further validate the results obtained by the FA-based assay. Overall, the present study demonstrates that the FA-based assay using the substrate pair R-I-Cad and DMC represents a facile, homogenous and continuous method for quantifying TGase 2 activity in cell lysates.
In addition to the classic functions of proteins, such as acting as a biocatalyst or binding partner, the conformational states of proteins and their remodeling upon stimulation need to be considered. A prominent example of a protein that undergoes comprehensive conformational remodeling is transglutaminase 2 (TGase 2), the distinct conformational states of which are closely related to particular functions. Its involvement in various pathophysiological processes, including fibrosis and cancer, motivates the development of theranostic agents, particularly based on inhibitors that are directed toward the transamidase activity. In this context, the ability of such inhibitors to control the conformational dynamics of TGase 2 emerges as an important parameter, and methods to assess this property are in great demand. Herein, we describe the application of the switchSENSE® principle to detect conformational changes caused by three irreversibly binding Nε-acryloyllysine piperazides, which are suitable radiotracer candidates of TGase 2. The switchSENSE® technique is based on DNA levers actuated by alternating electric fields. These levers are immobilized on gold electrodes with one end, and at the other end of the lever, the TGase 2 is covalently bound. A novel computational method is introduced for describing the resulting lever motion to quantify the extent of stimulated conformational TGase 2 changes. Moreover, as a complementary biophysical method, native polyacrylamide gel electrophoresis was performed under similar conditions to validate the results. Both methods prove the occurrence of an irreversible shift in the conformational equilibrium of TGase 2, caused by the binding of the three studied Nε-acryloyllysine piperazides.
Background: There is a need for person-centred outcome measures (PCOMs) in tuberculosis (TB) clinical trials to capture the priorities of affected individuals relating to both disease and treatment, alongside the traditional efficacy and safety analysis. Methods: We conducted a literature search to identify existing health-related quality-of-life (HR-QoL) measurement tools and instances where they have been used to evaluate TB disease in interventional studies. DR-TB survivors were recruited for focus group discussions in South Africa, Mongolia and Georgia to determine the most important aspects of disease and treatment experience from their perspective. A second round of focus groups then worked to prioritise these items and group them within different domains. A panel of researchers and academic clinicians evaluated existing PCOMs identified in the literature search using a published framework. Finally, an assessment was carried out by a experienced TB Community Advisory Group members for appropriateness and acceptability, and clinical trial site investigators for feasibility of the PCOMs. Results: The initial round of 9 focus groups involving 57 participants identified priority items grouped under the fields “overall quality of life”, “disease symptoms”, and “treatment and side effects”. In the second round of four focus groups involving 26 participants, the highest ranked items under “overall quality of life” were duration of treatment, experience of swallowing pills, and how long before being able to contribute to the household. The most important symptoms were coughing, weight loss and breathlessness. The highest ranked side effects were nausea/vomiting, skin colour changes, and nerve problems. FACIT-TB was the only measurement tool assessed that was rated “good” for appropriateness, and “excellent”, “good” or “fair” in all other fields by community representatives, researchers and clinical trial site staff. Conclusions: The FACIT-TB measurement tool was identified as the most appropriate disease-specific PCOM currently available for use in clinical trials investigating novel DR-TB therapeutics.